Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Follicular 5Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Advanced Solid Tumors 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × duvelisib × Clear all
NCT02204982 2023-09-28

DYNAMO + R

SecuraBio

Phase 3 Terminated
13 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02598570 2017-02-06

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

AbbVie

Phase 1 Completed
7 enrolled
Lymphoid

Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡